Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
César Serrano(Vall d'Hebron Institut de Recerca), Jonathan A. Fletcher(Borders General Hospital)
Cited by 165
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996
Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
|Journal of Clinical Oncology|2013|594
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
|PLoS ONE|2009|433